Iterum Therapeutics plc - Ordinary Share (ITRM): Price and Financial Metrics

Iterum Therapeutics plc - Ordinary Share (ITRM): $1.26

0.04 (-2.71%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add ITRM to Watchlist
Sign Up

ITRM Price/Volume Stats

Current price $1.26 52-week high $2.50
Prev. close $1.29 52-week low $0.62
Day low $1.22 Volume 158,422
Day high $1.31 Avg. volume 363,907
50-day MA $1.32 Dividend yield N/A
200-day MA $1.44 Market Cap 20.78M

ITRM Stock Price Chart Interactive Chart >


Iterum Therapeutics plc - Ordinary Share (ITRM) Company Bio


Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is based in Dublin, Ireland.


ITRM Latest News Stream


Event/Time News Detail
Loading, please wait...

ITRM Latest Social Stream


Loading social stream, please wait...

View Full ITRM Social Stream

Latest ITRM News From Around the Web

Below are the latest news stories about ITERUM THERAPEUTICS PLC that investors may wish to consider to help them evaluate ITRM as an investment opportunity.

Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule

DUBLIN, Ireland and CHICAGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained com

Yahoo | December 4, 2023

Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call Transcript

Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Hello, everyone, and welcome to the Iterum Therapeutics Third Quarter 2023 Financial Results and Business Update. My name is Harry, and I’ll be your operator today. [Operator Instructions] And I will now hand the call over to Louise Barrett, Senior Vice President, […]

Yahoo | November 15, 2023

Q3 2023 Iterum Therapeutics PLC Earnings Call

Q3 2023 Iterum Therapeutics PLC Earnings Call

Yahoo | November 15, 2023

Iterum Therapeutics Reports Third Quarter 2023 Financial Results

-- Top-line Data for Pivotal REASSURE Trial Expected in Early Q1 2024 – --Resubmission of NDA for uUTI Expected in Q2 2024-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ende

Yahoo | November 14, 2023

Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023

DUBLIN, Ireland and CHICAGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, November 14, 2023. Management will

Yahoo | November 7, 2023

Read More 'ITRM' Stories Here

ITRM Price Returns

1-mo 7.69%
3-mo -19.75%
6-mo -26.74%
1-year 21.15%
3-year -92.57%
5-year -98.71%
YTD -36.04%
2023 134.52%
2022 -85.71%
2021 -60.38%
2020 -78.02%
2019 -10.18%

Continue Researching ITRM

Want to see what other sources are saying about Iterum Therapeutics plc's financials and stock price? Try the links below:

Iterum Therapeutics plc (ITRM) Stock Price | Nasdaq
Iterum Therapeutics plc (ITRM) Stock Quote, History and News - Yahoo Finance
Iterum Therapeutics plc (ITRM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!